[{"address1": "1185 Avenue of the Americas", "address2": "3rd Floor", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "973 242 0005", "website": "https://www.synaptogen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alan J. Tuchman M.D., MBA(FAAN)", "age": 76, "title": "CEO & Director", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 303347, "exercisedValue": 0, "unexercisedValue": 50088}, {"maxAge": 1, "name": "Dr. Daniel L. Alkon M.D.", "age": 81, "title": "President, Chief Scientific Officer & Director", "yearBorn": 1942, "fiscalYear": 2023, "totalPay": 375000, "exercisedValue": 0, "unexercisedValue": 109125}, {"maxAge": 1, "name": "Mr. Robert  Weinstein", "age": 63, "title": "CFO, Executive VP, Treasurer & Secretary", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 568918, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.54, "open": 2.75, "dayLow": 2.75, "dayHigh": 3.15, "regularMarketPreviousClose": 2.54, "regularMarketOpen": 2.75, "regularMarketDayLow": 2.75, "regularMarketDayHigh": 3.15, "beta": 1.427, "trailingPE": 3.4886363, "forwardPE": -0.35948476, "volume": 96244, "regularMarketVolume": 96244, "averageVolume": 20615, "averageVolume10days": 9080, "averageDailyVolume10Day": 9080, "marketCap": 4161722, "fiftyTwoWeekLow": 2.32, "fiftyTwoWeekHigh": 8.775, "fiftyDayAverage": 2.90888, "twoHundredDayAverage": 3.839915, "currency": "USD", "enterpriseValue": -23815614, "floatShares": 1288693, "sharesOutstanding": 1355610, "sharesShort": 5457, "sharesShortPriorMonth": 7976, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.004, "heldPercentInsiders": 0.01949, "heldPercentInstitutions": 0.0029300002, "shortRatio": 0.17, "shortPercentOfFloat": 0.0041, "impliedSharesOutstanding": 1355610, "bookValue": 25.267, "priceToBook": 0.121502355, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -3445093, "trailingEps": 0.88, "forwardEps": -8.54, "lastSplitFactor": "1:25", "lastSplitDate": 1712275200, "enterpriseToEbitda": 3.487, "52WeekChange": -0.63225806, "SandP52WeekChange": 0.2421279, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SNPX", "underlyingSymbol": "SNPX", "shortName": "Synaptogenix, Inc.", "longName": "Synaptogenix, Inc.", "firstTradeDateEpochUtc": 1607437800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d14ff140-0ac6-3af9-a386-f918dc6aa47f", "messageBoardId": "finmb_268943522", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.07, "targetHighPrice": 14.0, "targetLowPrice": 14.0, "targetMeanPrice": 14.0, "targetMedianPrice": 14.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 27414324, "totalCashPerShare": 20.858, "ebitda": -6829012, "quickRatio": 2.931, "currentRatio": 2.975, "returnOnAssets": -0.13819, "returnOnEquity": -0.07495, "freeCashflow": 2585062, "operatingCashflow": -4922985, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-21"}]